Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

776 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries.
Valgimigli M, Malagutti P, Rodriguez-Granillo GA, Garcia-Garcia HM, Polad J, Tsuchida K, Regar E, Van der Giessen WJ, de Jaegere P, De Feyter P, Serruys PW. Valgimigli M, et al. J Am Coll Cardiol. 2006 Apr 18;47(8):1530-7. doi: 10.1016/j.jacc.2005.11.066. Epub 2006 Mar 27. J Am Coll Cardiol. 2006. PMID: 16630987 Free article.
High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients.
Valgimigli M, Percoco G, Cicchitelli G, Ferrari F, Barbieri D, Ansani L, Guardigli G, Parrinello G, Malagutti P, Soukhomovskaia O, Bettini A, Campo G, Ferrari R. Valgimigli M, et al. Cardiovasc Drugs Ther. 2004 May;18(3):225-30. doi: 10.1023/B:CARD.0000033644.91126.f7. Cardiovasc Drugs Ther. 2004. PMID: 15229391 Clinical Trial.
Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study.
Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, Cicchitelli G, Olivares A, Parrinello G, Percoco G, Guardigli G, Mele D, Pirani R, Ferrari R. Valgimigli M, et al. Circulation. 2005 Feb 22;111(7):863-70. doi: 10.1161/01.CIR.0000155614.35441.69. Epub 2005 Feb 7. Circulation. 2005. PMID: 15699251
Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidance.
Agostoni P, Valgimigli M, Van Mieghem CA, Rodriguez-Granillo GA, Aoki J, Ong AT, Tsuchida K, McFadden EP, Ligthart JM, Smits PC, de Jaegere P, Sianos G, Van der Giessen WJ, De Feyter P, Serruys PW. Agostoni P, et al. Among authors: valgimigli m. Am J Cardiol. 2005 Mar 1;95(5):644-7. doi: 10.1016/j.amjcard.2004.10.042. Am J Cardiol. 2005. PMID: 15721110
Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH).
Valgimigli M, van Mieghem CA, Ong AT, Aoki J, Granillo GA, McFadden EP, Kappetein AP, de Feyter PJ, Smits PC, Regar E, Van der Giessen WJ, Sianos G, de Jaegere P, Van Domburg RT, Serruys PW. Valgimigli M, et al. Circulation. 2005 Mar 22;111(11):1383-9. doi: 10.1161/01.CIR.0000158486.20865.8B. Circulation. 2005. PMID: 15781749
The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.
Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Regar E, van der Ent M, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT. Ong AT, et al. Among authors: valgimigli m. J Am Coll Cardiol. 2005 Apr 5;45(7):1135-41. doi: 10.1016/j.jacc.2005.01.008. J Am Coll Cardiol. 2005. PMID: 15808774 Free article.
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile.
Valgimigli M, Rigolin GM, Cittanti C, Malagutti P, Curello S, Percoco G, Bugli AM, Della Porta M, Bragotti LZ, Ansani L, Mauro E, Lanfranchi A, Giganti M, Feggi L, Castoldi G, Ferrari R. Valgimigli M, et al. Eur Heart J. 2005 Sep;26(18):1838-45. doi: 10.1093/eurheartj/ehi289. Epub 2005 Apr 28. Eur Heart J. 2005. PMID: 15860518 Clinical Trial.
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R; STRATEGY Investigators. Valgimigli M, et al. JAMA. 2005 May 4;293(17):2109-17. doi: 10.1001/jama.293.17.2109. JAMA. 2005. PMID: 15870414 Clinical Trial.
776 results